FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
Brean Capital reiterated a Buy rating and $40 price target on Horizon Pharma (NASDAQ: HZNP) following the release of its 2Q15 earnings results. revenue was $172.8 million beating consensus estimates of $156.4. Non-GAAP EPS was $0.39 beating consensus' $0.32.
Analyst Difei Yang commented, "Given the pre-announcement of... More

